Literature DB >> 3547667

New agents and new medical treatments for advanced breast cancer.

I C Henderson, D F Hayes, S Come, J R Harris, G Canellos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3547667

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  12 in total

1.  A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer.

Authors:  T Langenbuch; K Mross; W Jonat; D K Hossfeld
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer.

Authors:  C Manegold; P Worst; J Bickel; H Schmid; P Drings; M Kaufmann
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Four-drug sequential regimen in advanced breast cancer.

Authors:  L Ferrari; E Bajetta; L Gianni; C Verusio; C Bartoli; P Valagussa; G Bonadonna
Journal:  Breast Cancer Res Treat       Date:  1987-11       Impact factor: 4.872

Review 4.  Breast cancer. Advances in management.

Authors:  G N Brodie; A Elefanty
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

5.  Elevated plasma tamoxifen levels in a patient with liver obstruction.

Authors:  M W DeGregorio; V J Wiebe; A P Venook; W M Holleran
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Sequential hormonochemotherapy in advanced breast cancer.

Authors:  L L Hart
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-23

7.  Ifosfamide combination chemotherapy in advanced breast cancer.

Authors:  H Schmid; M Kaufmann; E M Grischke; G Bastert
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  Weekly 5-fluorouracil and high-dose folinic acid in combination with epidoxorubicin as first-line therapy in advanced breast cancer: a phase II study.

Authors:  H Stöger; T Bauernhofer; A K Kasparek; M Schmid; R Moser; F Ploner; E Derstvenscheg; I Kuss; M Wilders-Truschnig; P Steindorfer
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients.

Authors:  H Stöger; T Bauernhofer; M Schmid; F Ploner; R Moser; E Derstvenscheg; P Steindorfer; M Wilders-Truschnig; I Kuss; H Samonigg
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  Prognostic factors in locally advanced noninflammatory breast cancer. Long-term results following primary chemotherapy.

Authors:  P Valagussa; M Zambetti; G Bonadonna; R Zucali; G Mezzanotte; U Veronesi
Journal:  Breast Cancer Res Treat       Date:  1990-05       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.